The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Peregrine Pharmaceuticals
Stock and Other Ownership Interests - Peregrine Pharmaceuticals
PPHM 1501- An open-label, randomized, phase II trial of durvalumab (MEDI4736) with or without bavituximab in patients with previously treated metastatic non-small cell lung cancer (NSCLC): Safety report on first 18 patients.
 
Ronald B. Natale
Employment - AstraZeneca (I)
Consulting or Advisory Role - Genentech/Roche; Lilly
Research Funding - Amgen; AstraZeneca; Clovis Oncology; Lilly; Peregrine Pharmaceuticals
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
 
Rachel E. Sanborn
Consulting or Advisory Role - Amgen
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Alberto Chiappori
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Genentech; Novartis; Pfizer
Speakers' Bureau - Boehringer Ingelheim; Celgene; Genentech; Merck; Novartis; Pfizer
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Konstantin H. Dragnev
No Relationships to Disclose
 
Joseph Shan
Employment - Peregrine Pharmaceuticals
Leadership - Peregrine Pharmaceuticals
Stock and Other Ownership Interests - Peregrine Pharmaceuticals
 
Lisa Stepp
No Relationships to Disclose
 
Michael McCleod
No Relationships to Disclose
 
David Michael Waterhouse
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Research Funding - ArQule (Inst); BerGenBio (Inst); Celgene (Inst); Genentech (Inst); ImClone Systems (Inst); Immunogen (Inst); Synta (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
Travel, Accommodations, Expenses - ArQule; Lilly; Lilly